Search results
AbbVie (ABBV) Could Be a Great Choice
Zacks via Yahoo Finance· 2 days agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?...
AbbVie Reports First-Quarter 2024 Financial Results
The Hannibal Courier-Post· 7 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 17 hours agoMerck & Co- $30.5bn Merck & Co’s revenues reached $60.1bn in FY 2023, with R&D investments peaking at $30.5bn. Displaying a staggering 126% growth...
New Cancer 'Missile' Drugs May Be More Effective Than Traditional Chemotherapy
Verywell Health via Yahoo News· 8 hours agoThe treatment, Elahere (mirvetuximab soravtansine), is for patients with late-stage disease who have...
Trials to watch: Four ALS drugs to keep an eye on
Clinical Trials Arena via Yahoo Finance· 2 days agoHEALEY Platform trial investigates Calico and AbbVie drug The HEALEY ALS Platform Trial (NCT04297683) is a perpetual multi-centre... is a Phase II/III...
Noninvasive Brain Stimulation Shows Rapid Relief for MDD
Medscape· 19 hours agoAn RCT suggests transcranial alternating current stimulation may be an effective treatment for major...
Two Biosimilars Approved in Europe for Autoimmune Disorders
Medscape· 7 days agoThe drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's...
Addex stock tanks after lead drug flops in Phase II epilepsy trial
Clinical Trials Arena via Yahoo Finance· 3 days agoThe use of PAMs for treating neurological disorders has been an area of focus in recent months. In...
JD Supra: Update on biosimilars in Canada – March 2024
JD Supra· 6 days agoIn this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access) since our March...
Lower CVD Risk With Stable DMARD Therapy in Seropositive RA
Medscape· 19 hours agoPatients with seropositive RA on stable DMARD therapy showed a CVD risk comparable with that of the...
